GlassScriptPhysician profile
Richard Burns
NPI 1902856818
$78,751.42
in general payments reported to CMS, 2019-2025
17 companies · $740 in 2025
The $740 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $758 · 2020: $1,017 · 2021: $74K · 2022: $697 · 2023: $396 · 2024: $758 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,894.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $76,982.13 | 2019-2025 | Clareon, Argos, Rocklatan |
| Glaukos Corporation | $343.94 | 2020-2025 | Ce-Marked Kxla System, Idosetr, Photrexa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $231.25 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $201.57 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $199.04 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $155.95 | 2019-2021 | |
| Rxsight INC | $142.16 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Biotissue Holdings INC. | $89.08 | 2020 | |
| Dompe US, INC. | $82.41 | 2022-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $79.55 | 2022-2025 | Xiidra, Miebo, Envista Envy Iol |
| Abbvie INC. | $70.11 | 2022-2025 | Vuity, Alphagan P, Lumigan |
| Harrow Eye, LLC | $41.23 | 2024-2025 | Vevye |
| Boston Scientific Corporation | $39.82 | 2023 | Wavewriter Alpha Prime 16 |
| Oyster Point Pharma, INC. | $35.94 | 2022 | |
| Ocular Therapeutix, INC. | $24.09 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $17.70 | 2020 | |
| Eyevance Pharmaceuticals LLC | $15.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.